Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells 17,604 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 17,604 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $20.05, for a total value of $352,960.20. Following the completion of the sale, the executive vice president now directly owns 284,442 shares of the company’s stock, valued at approximately $5,703,062.10. This represents a 5.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

BioLife Solutions Trading Up 1.5 %

BLFS opened at $25.39 on Friday. BioLife Solutions, Inc. has a 52 week low of $11.91 and a 52 week high of $28.88. The business has a fifty day simple moving average of $23.96 and a 200-day simple moving average of $22.88. The firm has a market cap of $1.18 billion, a P/E ratio of -23.95 and a beta of 1.88. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BLFS. Swiss National Bank boosted its holdings in BioLife Solutions by 3.6% in the first quarter. Swiss National Bank now owns 71,100 shares of the medical equipment provider’s stock valued at $1,319,000 after purchasing an additional 2,500 shares during the period. Sei Investments Co. boosted its holdings in BioLife Solutions by 1.4% in the first quarter. Sei Investments Co. now owns 60,191 shares of the medical equipment provider’s stock valued at $1,117,000 after purchasing an additional 839 shares during the period. Russell Investments Group Ltd. boosted its holdings in BioLife Solutions by 6.1% in the first quarter. Russell Investments Group Ltd. now owns 194,126 shares of the medical equipment provider’s stock valued at $3,601,000 after purchasing an additional 11,076 shares during the period. State Board of Administration of Florida Retirement System purchased a new position in BioLife Solutions in the first quarter valued at $229,000. Finally, Vanguard Group Inc. boosted its holdings in BioLife Solutions by 11.5% in the first quarter. Vanguard Group Inc. now owns 2,868,335 shares of the medical equipment provider’s stock valued at $53,208,000 after purchasing an additional 296,727 shares during the period. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on BLFS shares. Northland Securities increased their price target on BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Craig Hallum raised their target price on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. TD Cowen raised their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, HC Wainwright cut their target price on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Monday. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $27.50.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.